TECX Tectonic Therapeutic, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1681087 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-30.9%
TTM EPS YoY-72.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-35.5%
ROA-33.8%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets6.0%
Debt / equity0.00x
Current ratio19.71x
Interest coverage-3,216.43x
Cash quality & payout
Operating cash flow / net income0.79x
Accruals ratio-7.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $17.44M | $18.05M | $20.87M | $16.34M | $16.93M | $17.18M | $13.04M | $9.16M |
| SG&A expense | $6.01M | $6.17M | $6.43M | $5.17M | $4.96M | $5.15M | $5.26M | $6.75M |
| Operating income | -$23.46M | -$24.22M | -$27.30M | -$21.52M | -$21.89M | -$22.33M | -$18.30M | -$13.99M |
| Interest expense | $4,000 | $6,000 | $8,000 | $12,000 | $14,000 | $17,000 | $20,000 | $22,000 |
| Pretax income | -$21.35M | -$22.21M | — | -$18.97M | -$19.04M | -$19.01M | — | -$12.37M |
| Income tax | $0 | $77,000 | — | $254,000 | $0 | $976,000 | — | $0 |
| Net income | -$21.35M | -$22.29M | -$25.24M | -$19.23M | -$19.04M | -$19.98M | -$15.91M | -$12.37M |
| EBITDA | -$23.21M | -$23.93M | -$27.00M | -$21.18M | -$21.55M | -$21.99M | -$17.94M | -$13.48M |
| EPS (basic) | -1.08 | -1.18 | -1.34 | — | -1.02 | -1.07 | -0.93 | — |
| EPS (diluted) | -1.08 | -1.18 | -1.34 | — | -1.02 | -1.07 | -0.93 | — |
| Dividends declared per share | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 19.70M | 18.96M | 18.77M | — | 18.71M | 18.68M | 17.16M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $234.67M | $227.07M | $236.89M | $253.80M | $268.44M | $287.38M | $306.25M | $141.83M |
| Current assets | $238.55M | $231.10M | $239.89M | $257.36M | $273.24M | $290.85M | $309.64M | $146.86M |
| PP&E, net | $793,000 | $858,000 | $1.02M | $1.19M | $1.41M | $1.68M | $1.92M | $2.15M |
| Total assets | $243.86M | $237.03M | $246.58M | $261.04M | $277.00M | $295.31M | $314.83M | $152.91M |
| Current liabilities | $12.10M | $10.37M | $12.96M | $9.67M | $9.37M | $11.36M | $13.51M | $11.61M |
| Total liabilities | $14.54M | $13.19M | $16.16M | $9.71M | $9.47M | $11.55M | $13.79M | $12.13M |
| Shareholders' equity | $229.32M | $223.85M | $230.42M | $251.33M | $267.53M | $283.77M | $301.04M | $140.78M |
| Shares outstanding | 19.94M | 19.24M | 18.83M | 18.74M | 18.71M | 18.71M | 18.67M | 14.86M |
| Cash flow statement | ||||||||
| Operating cash flow | -$14.91M | -$21.45M | -$18.41M | -$14.46M | -$17.82M | -$14.72M | -$13.08M | -$16.82M |
| Capital expenditure | $0 | $79,000 | $19,000 | $0 | $181,000 | $0 | $27,000 | $3,000 |
| Free cash flow | -$14.91M | -$21.53M | -$18.43M | -$14.46M | -$18.00M | -$14.72M | -$13.11M | -$16.82M |
| Investing cash flow | $0 | -$59,000 | -$19,000 | $0 | -$166,000 | $55,000 | -$27,000 | -$3,000 |
| Financing cash flow | $22.50M | $11.68M | $847,000 | -$141,000 | -$457,000 | -$4.17M | $178.12M | -$1.07M |
| Depreciation & amortization | $250,000 | $285,000 | $304,000 | $333,000 | $342,000 | $340,000 | $360,000 | $508,000 |
| Stock-based compensation | $4.24M | $4.01M | $3.21M | $2.99M | $2.82M | $2.59M | $2.10M | $1.12M |
Free plan shows the latest 8 periods; Pro shows all 38 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.